Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 12/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | RORC | P51449 | 1/20 | 0.48 |
| ▸ | RHOA | P61586 | 3/20 | 0.44 |
| ▸ | RHOC | P08134 | 2/20 | 0.44 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.43 |
| ▸ | TACR2 | P21452 | 1/20 | 0.43 |
| ▸ | TAC3 | Q9UHF0 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6442815 | 1.00 | TACR1 (0.52) | TACR1CYP3A4CYP2D6CYP2C9RORC | |
| SCHEMBL6441492 | 0.94 | RHOA (0.49) | TACR1CYP3A4CYP2C9RHOARHOC | |
| SCHEMBL6441487 | 0.94 | RHOA (0.49) | TACR1CYP3A4CYP2C9RHOARHOC | |
| SCHEMBL6443352 | 0.92 | SLC18A3 (0.50) | TACR1CYP3A4RHOARHOCSLC18A3 | |
| SCHEMBL6443346 | 0.92 | SLC18A3 (0.50) | TACR1CYP3A4RHOARHOCSLC18A3 | |
| SCHEMBL6440261 | 0.92 | RHOA (0.45) | TACR1CYP3A4RHOARHOCSLC18A3 | |
| SCHEMBL6440256 | 0.92 | RHOA (0.45) | TACR1CYP3A4RHOARHOCSLC18A3 | |
| SCHEMBL5918122 | 0.91 | HIF1A (0.47) | TACR1CYP3A4RHOARHOCSLC18A3 | |
| SCHEMBL5800189 | 0.91 | HIF1A (0.47) | TACR1CYP3A4RHOARHOCSLC18A3 | |
| SCHEMBL6442173 | 0.90 | KDM1A (0.46) | TACR1CYP3A4CYP2C9RHOARHOC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1360184-B1 | PIPERIDINE DERIVATIVES AS NEUROKININ 1 ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2005-03-30 | — | — | EP | disclosed |
| US-6642226-B2 | Such as cis-(3,5-bis-trifluoromethyl-phenyl)-(4-(4-methyl-piperazin-1-yl),-3-phenyl -piperidin-1-yl)-methanone; for treatment of diseases related to neurokinin receptors | HOFFMAN-LA ROCHE INC. | 2003-11-04 | — | — | US | disclosed |
| US-20020151547-A1 | Substituted phenyl-piperidine methanone compounds | F.HOFFMANN-LA ROCHE AG (CH) | 2002-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020151547-A1 | Substituted phenyl-piperidine methanone compounds | TACR1, OPRK1, TACR2 | TACR1 1/4885CYP3A4 1266/4885CYP2D6 676/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.